Candel Therapeutics, Inc. (NASDAQ:CADL) Major Shareholder Estuardo Aguilar-Cordova Sells 15,000 Shares

Candel Therapeutics, Inc. (NASDAQ:CADL) major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of the stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $6.02, for a total value of $90,300.00. Following the transaction, the insider now owns 929,873 shares in the company, valued at $5,597,835.46. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Estuardo Aguilar-Cordova also recently made the following trade(s):

• On Friday, October 11th, Estuardo Aguilar-Cordova sold 15,000 shares of Candel Therapeutics stock. The stock was sold at an average price of $6.05, for a total value of $90,750.00.
• On Thursday, October 3rd, Estuardo Aguilar-Cordova sold 1,800 shares of Candel Therapeutics stock. The stock was sold at an average price of $6.85, for a total value of $12,330.00.

Candel Therapeutics Trading Down 0.8 %

Shares of Candel Therapeutics stock traded down $0.05 on Tuesday, reaching $5.95. 240,111 shares of the company’s stock were exchanged, compared to its average volume of 1,991,057. The company has a market capitalization of $177.05 million, a P/E ratio of -4.65 and a beta of -0.95. Candel Therapeutics, Inc. has a 52 week low of $0.66 and a 52 week high of $14.30. The firm’s 50-day moving average is $6.31 and its two-hundred day moving average is $6.81. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.62 and a current ratio of 1.62.

Candel Therapeutics (NASDAQ:CADL) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.74) earnings per share (EPS) for the quarter. Sell-side analysts predict that Candel Therapeutics, Inc. will post -0.91 EPS for the current fiscal year.

Hedge Funds Weigh In On Candel Therapeutics

A number of large investors have recently modified their holdings of CADL. Bank of New York Mellon Corp bought a new position in shares of Candel Therapeutics in the 2nd quarter worth $338,000. Cubist Systematic Strategies LLC bought a new position in shares of Candel Therapeutics in the 2nd quarter worth $162,000. Rhumbline Advisers bought a new position in shares of Candel Therapeutics in the 2nd quarter worth $143,000. Finally, Point72 DIFC Ltd bought a new position in shares of Candel Therapeutics in the 2nd quarter worth $31,000. 13.93% of the stock is currently owned by institutional investors.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.